Analysis of the clinical characteristics of 100 patients who developed tuberculosis after renal transplantation.

Publication date: Jun 04, 2025

The early clinical diagnosis of tuberculosis (TB) in kidney transplant recipients is difficult, and TB is one of the major infectious disease-related causes of morbidity and death in transplant recipients. This study analyzed the characteristics of patients who developed TB after renal transplantation in an effort to improve the diagnosis and treatment of such patients. This retrospective study examined 100 patients who developed TB after kidney transplantation, and received treatment at the Hunan Chest Hospital from January 2014 to January 2024. The clinical characteristics of patients were examined, including general condition, date of TB onset, clinical manifestations, site of TB, immunological indicators, method of etiological detection, imaging findings, treatment, and outcome. Secondary pulmonary TB was the most common diagnosis overall (n = 76), and abdominal TB was the most common type of extrapulmonary TB (n = 8). Eighty-eight patients were tested by the interferon-gamma release assay (IGRA); 72 (81. 8%) had positive results, 13 (14. 8%) had negative results, and 3 (3. 4%) had uncertain results. Twenty-six patients received the tuberculin skin test (TST); 7 (26. 9%) had positive results and 19 (73. 1%) had negative results. The overall etiological detection rate was 58. 0%. Analysis of factors associated with outcome showed that patients who received an intensive phase regimen of isoniazid + rifampicin + ethambutol + moxifloxacin were more likely to achieve cure than those who received an intensive phase regimen of isoniazid + rifampicin + ethambutol + pyrazinamide (P 

Open Access PDF

Concepts Keywords
Eighty Clinical characteristics
Hunan Moxifloxacin
Kidney Outcome
Pyrazinamide Renal transplantation
Tuberculosis Tuberculosis

Semantics

Type Source Name
disease MESH tuberculosis
pathway KEGG Tuberculosis
disease MESH infectious disease
pathway REACTOME Infectious disease
disease MESH causes
disease MESH morbidity
disease MESH death
disease IDO site
pathway REACTOME Release
disease IDO assay
drug DRUGBANK Moxifloxacin
drug DRUGBANK Pyrazinamide
pathway REACTOME Reproduction
drug DRUGBANK Coenzyme M

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *